Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Sonodynamic Cancer Therapy
share announcement

Sonodynamic Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 3951

Special Issue Editors

Dr. Francesco Prada

E-Mail Website
Guest Editor
Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico “C. Besta”, 20133 Milan, Italy
Interests: ultrasound; sonodynamic therapy; brain tumor; neurosurgery; vascular surgery; neuro-oncology; intraoperative imaging; skull base surgery; spinal cord tumor; fusion imaging
Prof. Dr. Eleanor Stride

E-Mail Website
Guest Editor
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Medical Sciences Division, University of Oxford, Oxford, UK
Interests: targeted delivery; microbubbles; nanomaterials; sonodynamic therapy; ultrasound
Dr. Loredana Serpe

E-Mail Website
Guest Editor
Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy
Interests: ultrasound; sonodynamic therapy; cavitation; cancer; pharmacology; drug delivery; toxicology
Dr. Kismet Hossain-Ibrahim

E-Mail Website
Guest Editor
School of Medicine, University of Dundee, Dundee, UK
Interests: ultrasound; neurosurgery; neuro-oncology; brain tumor; regenerative medicine; skull-base surgery; sonodynamic therapy

Special Issue Information

Dear Colleagues,

Sonodynamic therapy (SDT) is emerging as a new tool to fight cancer in a non-invasive fashion. SDT employs the interaction between low-intensity focused ultrasound and a non-toxic sound-sensitive chemical agent that selectively accumulates in the tumoral area, which is called a “sonosensitizer”. In vitro studies and in vivo animal models have been conducted to deepen our understanding of this new technique to be applied against melanoma, breast cancer, gliomas, and other tumors. As a matter of fact, a transition from bench to bedside is currently ongoing, with numerous clinical trials approved and open to enrollment, tackling various forms of cancer, investigating, for example, the role 5-aminolevulinic acid-mediated SDT in high-grade glioma patients. Despite its clinical translation mechanism of action, bioeffects, sensitizers, and ultrasound parameters still need to be further understood. In fact, new sonosensitizers are under investigation, such as fluorescein and nanoparticles, while SDT is also being evaluated in combination with radiotherapy, chemotherapy, and immunotherapy in a multimodal synergistic perspective.

Cancers calls for papers and invites researchers to submit their abstracts for this new Special Issue titled “Sonodynamic Cancer Therapy”. The purpose of the Issue is to raise awareness about sonodynamic treatment against tumors, and to further promote this research field.

This Special Issue welcomes both original research articles and reviews.

Dr. Francesco Prada
Prof. Dr. Eleanor Stride
Dr. Loredana Serpe
Dr. Kismet Hossain-Ibrahim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sonodynamic therapy
  • cancer treatment
  • sonosensitizer
  • focused ultrasound
  • 5-Aminolevulinic acid
  • fluorescein
  • nanomedicine
  • synergistic therapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 15593 KiB  
Article
The Immunomodulatory Effects of Fluorescein-Mediated Sonodynamic Treatment Lead to Systemic and Intratumoral Depletion of Myeloid-Derived Suppressor Cells in a Preclinical Malignant Glioma Model
by Serena Pellegatta, Nicoletta Corradino, Manuela Zingarelli, Edoardo Porto, Matteo Gionso, Arianna Berlendis, Gianni Durando, Martina Maffezzini, Silvia Musio, Domenico Aquino, Francesco DiMeco and Francesco Prada
Cancers 2024, 16(4), 792; https://doi.org/10.3390/cancers16040792 - 15 Feb 2024
Viewed by 878
Abstract
Fluorescein-mediated sonodynamic therapy (FL-SDT) is an extremely promising approach for glioma treatment, resulting from the combination of low-intensity focused ultrasound (FUS) with a sonosensitizer. In the present study, we evaluated the efficacy and immunomodulation of SDT with fluorescein as the sonosensitizer in immunocompetent [...] Read more.
Fluorescein-mediated sonodynamic therapy (FL-SDT) is an extremely promising approach for glioma treatment, resulting from the combination of low-intensity focused ultrasound (FUS) with a sonosensitizer. In the present study, we evaluated the efficacy and immunomodulation of SDT with fluorescein as the sonosensitizer in immunocompetent GL261 glioma mice for the first time. In vitro studies demonstrated that the exposure of GL261 cells to FL-SDT induced immunogenic cell death and relevant upregulation of MHC class I, CD80 and CD86 expression. In vivo studies were then performed to treat GL261 glioma-bearing mice with FL-SDT, fluorescein alone, or FUS alone. Perturbation of the glioma-associated macrophage subset within the immune microenvironment was induced by all the treatments. Notably, a relevant depletion of myeloid-derived suppressor cells (MDSCs) and concomitant robust infiltration of CD8+ T cells were observed in the SDT-FL-treated mice, resulting in a significant radiological delay in glioma progression and a consequent improvement in survival. Tumor control and improved survival were also observed in mice treated with FL alone (median survival 41.5 days, p > 0.0001 compared to untreated mice), reflecting considerable modulation of the immune microenvironment. Interestingly, a high circulating lymphocyte-to-monocyte ratio and a very low proportion of MDSCs were predictive of better survival in FL- and FL-SDT-treated mice than in untreated and FUS-treated mice, in which elevated monocyte and MDSC frequencies correlated with worse survival. The immunostimulatory potential of FL-SDT treatment and the profound modulation of most immunosuppressive components within the microenvironment encouraged the exploration of the combination of FL-SDT with immunotherapeutic strategies. Full article
(This article belongs to the Special Issue Sonodynamic Cancer Therapy)
►▼ Show Figures

Figure 1

11 pages, 1312 KiB  
Article
Evaluation the Effect of Sonodynamic Therapy with 5-Aminolevulinic Acid and Sodium Fluorescein by Preclinical Animal Study
by Chiung-Yin Huang, Jui-Chin Li, Ko-Ting Chen, Ya-Jui Lin, Li-Ying Feng, Hao-Li Liu and Kuo-Chen Wei
Cancers 2024, 16(2), 253; https://doi.org/10.3390/cancers16020253 - 5 Jan 2024
Cited by 1 | Viewed by 972
Abstract
Sonodynamic therapy (SDT) is a novel tumor treatment that combines biosafe sonosensitizers and noninvasive focused ultrasound to eradicate solid tumors. Sonosensitizers such as 5-aminolevulinic acid and fluorescein have great potential in tumor treatment. Here, rodent subcutaneous and brain tumor models were used to [...] Read more.
Sonodynamic therapy (SDT) is a novel tumor treatment that combines biosafe sonosensitizers and noninvasive focused ultrasound to eradicate solid tumors. Sonosensitizers such as 5-aminolevulinic acid and fluorescein have great potential in tumor treatment. Here, rodent subcutaneous and brain tumor models were used to evaluate the treatment effect of both 5-ALA- and fluorescein-mediated SDT. The subcutaneous tumor growth rates of both SDT groups were significantly inhibited compared with that of the control groups. For intracranial tumors, 5-ALA-SDT treatment significantly inhibited brain tumor growth, while fluorescein-SDT exerted no therapeutic effect in animals. The distribution of fluorescein in the brain tumor region underwent further assessment. Seven days post tumor implantation, experimental animals received fluorescein and were sacrificed for brain specimen collection. Analysis of the dissected brains revealed no fluorescence signals, indicating an absence of fluorescein accumulation in the early-stage glioma tissue. These data suggest that the fluorescein-SDT treatment response is closely related to the amount of accumulated fluorescein. This study reports the equivalent effects of 5-ALA and fluorescein on the treatment of somatic tumors. For orthotopic brain tumor models, tumor vascular permeability should be considered when choosing fluorescein as a sonosensitizer. In conclusion, both fluorescein and 5-ALA are safe and effective SDT sonosensitizers, and the tumor microenvironment and pathologic type should be considered in the selection of adequate sonosensitizers. Full article
(This article belongs to the Special Issue Sonodynamic Cancer Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 3312 KiB  
Review
Theranostic Uses of the Heme Pathway in Neuro-Oncology: Protoporphyrin IX (PpIX) and Its Journey from Photodynamic Therapy (PDT) through Photodynamic Diagnosis (PDD) to Sonodynamic Therapy (SDT)
by Stuart L. Marcus and Mark P. de Souza
Cancers 2024, 16(4), 740; https://doi.org/10.3390/cancers16040740 - 10 Feb 2024
Viewed by 1625
Abstract
ALA PDT, first approved as a topical therapy to treat precancerous skin lesions in 1999, targets the heme pathway selectively in cancers. When provided with excess ALA, the fluorescent photosensitizer PpIX accumulates primarily in cancer tissue, and ALA PDD is used to identify [...] Read more.
ALA PDT, first approved as a topical therapy to treat precancerous skin lesions in 1999, targets the heme pathway selectively in cancers. When provided with excess ALA, the fluorescent photosensitizer PpIX accumulates primarily in cancer tissue, and ALA PDD is used to identify bladder and brain cancers as a visual aid for surgical resection. ALA PDT has shown promising anecdotal clinical results in recurrent glioblastoma multiforme. ALA SDT represents a noninvasive way to activate ALA PDT and has the potential to achieve clinical success in the treatment of both intracranial and extracranial cancers. This review describes the creation and evolution of ALA PDT, from the treatment of skin cancers to PDD and PDT of malignant brain tumors and, most recently, into a noninvasive form of PDT, ALA SDT. Current clinical trials of ALA SDT for recurrent glioblastoma and high-grade gliomas in adults, and the first pediatric ALA SDT clinical trial for a lethal brainstem cancer, diffuse intrinsic pontine glioma (DIPG), are also described. Full article
(This article belongs to the Special Issue Sonodynamic Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop